UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 51

Sortiert nach

Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy

Journal of clinical oncology, 2013-08, Vol.31 (22), p.2783-2790

2013

Volltextzugriff (PDF)

Factors Predicting Late Recurrence for Estrogen Receptor―Positive Breast Cancer

JNCI : Journal of the National Cancer Institute, 2013-10, Vol.105 (19), p.1504-1511

2013

Volltextzugriff (PDF)

Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score

Journal of clinical oncology, 2015-03, Vol.33 (8), p.916-922

2015

Volltextzugriff (PDF)

Development and verification of the PAM50-based Prosigna breast cancer gene signature assay

BMC medical genomics, 2015-08, Vol.8 (1), p.54-54, Article 54

2015

Volltextzugriff (PDF)

The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer

Breast cancer research : BCR, 2018-07, Vol.20 (1), p.79-79, Article 79

2018

Volltextzugriff (PDF)

A gene expression assay for simultaneous measurement of microsatellite instability and anti-tumor immune activity

Journal for immunotherapy of cancer, 2019-01, Vol.7 (1), p.15-15, Article 15

2019

Volltextzugriff (PDF)

Correction to: A gene expression assay for simultaneous measurement of microsatellite instability and anti-tumor immune activity

Journal for immunotherapy of cancer, 2019-03, Vol.7 (1), p.76-76, Article 76

2019

Volltextzugriff (PDF)

Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens

BMC cancer, 2014-03, Vol.14 (1), p.177-177, Article 177

2014

Volltextzugriff (PDF)

Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study

Journal of clinical oncology, 2021-01, Vol.39 (2), p.126-135

2021

Volltextzugriff (PDF)

Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial

JAMA oncology, 2018-04, Vol.4 (4), p.545

2018

Volltextzugriff (PDF)

PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer

Journal of clinical oncology, 2018-03, Vol.36 (8), p.735-740

2018

Volltextzugriff (PDF)

Abstract P5-06-05: Discordant classification and outcomes between Prosigna and Oncotype Dx Recurrence Score for ER-positive, HER2-negative, node-negative breast cancer

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P5-P5-06-05

2020

Volltextzugriff (PDF)

Direct multiplexed measurement of gene expression with color-coded probe pairs

Nature biotechnology, 2008-03, Vol.26 (3), p.317-325

2008

Volltextzugriff (PDF)

Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay

Clinical cancer research, 2016-02, Vol.22 (3), p.560-566

2016

Volltextzugriff (PDF)

Abstract P3-07-05: Correlation between and molecular drivers of oncotype DX, prosigna, EndoPredict and breast cancer index: A TransATAC study

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P3-P3-07-05

2020

Volltextzugriff (PDF)

Gene expression signature development to decode breast cancer heterogeneity

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e24243-e24243

2018

Volltextzugriff (PDF)

Population-based Study of Prosigna-PAM50 and Outcome Among Postmenopausal Women With Estrogen Receptor-positive and HER2-negative Operable Invasive Lobular or Ductal Breast Cancer

Clinical breast cancer, 2020-08, Vol.20 (4), p.e423-e432

2020

Volltextzugriff (PDF)

Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors

Breast cancer research and treatment, 2016-08, Vol.159 (1), p.71-78

2016

Volltextzugriff (PDF)

Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial

JNCI : Journal of the National Cancer Institute, 2017-02, Vol.109 (2)

2017

Volltextzugriff (PDF)

Molecular Drivers of Onco type DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study

Journal of clinical oncology, 2021-01, Vol.39 (2), p.126-135

2021

Volltextzugriff (PDF)

Validating critical analytical variables of a multiplexed gene expression assay measuring tumor inflammation designed to predict response to anti-PD1 therapy

Journal of clinical oncology, 2018-02, Vol.36 (5_suppl), p.203-203

2018

Volltextzugriff (PDF)

The ability of PAM50 risk of recurrence score to predict 10-year distant recurrence in hormone receptor-positive postmenopausal women with special histological subtypes

Acta oncologica, 2018-01, Vol.57 (1), p.44-50

2018

Volltextzugriff (PDF)

Genomic profiling of tumors from patients with germline BRCA mutations

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.1533-1533

2018

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(48)

Publikationsform

Artikel
(50)
Dissertationen
(1)

Sprache

Englisch
(51)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy

Factors Predicting Late Recurrence for Estrogen Receptor―Positive Breast Cancer

Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score

Development and verification of the PAM50-based Prosigna breast cancer gene signature assay

The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer

Analytical validation of a novel comprehensive genomic profiling informed circulating tumor DNA monitoring assay for solid tumors

A gene expression assay for simultaneous measurement of microsatellite instability and anti-tumor immune activity

Correction to: A gene expression assay for simultaneous measurement of microsatellite instability and anti-tumor immune activity

Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens

Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study

Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial

PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer

Abstract P5-06-05: Discordant classification and outcomes between Prosigna and Oncotype Dx Recurrence Score for ER-positive, HER2-negative, node-negative breast cancer

The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer

Direct multiplexed measurement of gene expression with color-coded probe pairs

Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay

Abstract P3-07-05: Correlation between and molecular drivers of oncotype DX, prosigna, EndoPredict and breast cancer index: A TransATAC study

Gene expression signature development to decode breast cancer heterogeneity

Population-based Study of Prosigna-PAM50 and Outcome Among Postmenopausal Women With Estrogen Receptor-positive and HER2-negative Operable Invasive Lobular or Ductal Breast Cancer

Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors

Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial

Molecular Drivers of Onco type DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study

Validating critical analytical variables of a multiplexed gene expression assay measuring tumor inflammation designed to predict response to anti-PD1 therapy

The ability of PAM50 risk of recurrence score to predict 10-year distant recurrence in hormone receptor-positive postmenopausal women with special histological subtypes

Genomic profiling of tumors from patients with germline BRCA mutations

Suchergebnisse filtern